Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

Open access
van Thuijl, Hinke F., Mazor, Tali, Johnson, Brett E., Fouse, Shaun D., Aihara, Koki, Hong, Chibo, Malmström, Annika, Hallbeck, Martin, Heimans, Jan J., Kloezeman, Jenneke J., Stenmark-Askmalm, Marie, Lamfers, Martine L. M., Saito, Nobuhito, Aburatani, Hiroyuki, Mukasa, Akitake, Berger, Mitchell S., Söderkvist, Peter, Taylor, Barry S., Molinaro, Annette M., Wesseling, Pieter, Reijneveld, Jaap C., Chang, Susan M., Ylstra, Bauke, Costello, Joseph F.·2015·Acta Neuropathologica

Abstract

Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined. DNA hypermethylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter is associated with an improved response to TMZ treatment, while inactivation of the DNA mismatch repair (MMR) pathway is associated with therapeutic resistance and TMZ-induced mutagenesis. We previously demonstrated that TMZ treatment of LGG induces driver mutations in the RB and AKT–mTOR pathways, which may drive malignant progression to secondary GBM. To better understand the mechanisms underlying TMZ-induced mutagenesis and malignant progression, we explored the evolution of MGMT methylation and genetic alterations affecting MMR genes in a cohort of 34 treatment-naïve LGGs and their recurrences. Recurrences with TMZ-associated hypermutation had increased MGMT methylation compared to their untreated initial tumors and higher overall MGMT methylation compared to TMZ-treated non-hypermutated recurrences. A TMZ-associated mutation in one or more MMR genes was observed in five out of six TMZ-treated hypermutated recurrences. In two cases, pre-existing heterozygous deletions encompassing MGMT, or an MMR gene, were followed by TMZ-associated mutations in one of the genes of interest. These results suggest that tumor cells with methylated MGMT may undergo positive selection during TMZ treatment in the context of MMR deficiency.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-015-1403-6

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 175

Metadata

Authors
van Thuijl, H. F., Mazor, T., Johnson, B. E., Fouse, S. D., Aihara, K., Hong, C., Malmström, A., Hallbeck, M., Heimans, J. J., Kloezeman, J. J., Stenmark-Askmalm, M., Lamfers, M. L. M., Saito, N., Aburatani, H., Mukasa, A., Berger, M. S., Söderkvist, P., Taylor, B. S., Molinaro, A. M., Wesseling, P., Reijneveld, J. C., Chang, S. M., Ylstra, B., & Costello, J. F.
Venue
Acta Neuropathologica
Published
2015-02-28
Volume
129
Issue
4
Pages
597-607
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2071191831
Cited by
175
References
2
FWCI
10.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. https://app.cochat.ai/papers/10.1007/s00401-015-1403-6
The paper
van Thuijl, H. F., Mazor, T., Johnson, B. E., Fouse, S. D., Aihara, K., Hong, C., Malmström, A., Hallbeck, M., Heimans, J. J., Kloezeman, J. J., Stenmark-Askmalm, M., Lamfers, M. L. M., Saito, N., Aburatani, H., Mukasa, A., Berger, M. S., Söderkvist, P., Taylor, B. S., Molinaro, A. M., . . . Costello, J. F. (2015). Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathologica. https://doi.org/10.1007/s00401-015-1403-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.